FNDC5/Irisin、Metrnl与老年肌少症的研究进展

doi:10.3969/j.issn.1003-9198.2022.05.024

摘要/Abstract

中图分类号:

R 746

赵亚男, 习玲. FNDC5/Irisin、Metrnl与老年肌少症的研究进展[J]. 实用老年医学, 2022, 36(5): 528-531.

[1] SIDDHARTH J,CHAKRABARTI A,PANNÉREC A,et al.Aging and sarcopenia associate with specific interactions between gut microbes, serum biomarkers and host physiology in rats[J]. Aging: Albany NY, 2017,9(7):1698-1714.
[2] NATIONS U. World population prospects[M]. New York: United Nations Publications,2017: 1-11.
[3] SZLEJF C, SUEMOTO C K, JANOVSKY C C P S,et al.Thyroid function and sarcopenia: results from the ELSA-Brasil Study[J]. J Am Geriatr Soc, 2020, 68(7): 1545-1553.
[4] ZHAO M, ZHOU X, YUAN C,et al.Association between serum irisin concentrations and sarcopenia in patients with liver cirrhosis: a cross-sectional study[J]. Sci Rep,2020,10(1):16093.
[5] BATSIS J A, VILLAREAL D T.Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies[J]. Nat Rev Endocrinol,2018, 14(9): 513-537.
[6] PARIS M T, BELL K E, MOURTZAKIS M.Myokines and adipokines in sarcopenia: understanding cross-talk between skeletal muscle and adipose tissue and the role of exercise[J]. Curr Opin Pharmacol, 2020,52(6):61-66.
[7] JODEIRI FARSHBAF M, ALVIÑA K.Multiple roles in neuroprotection for the exercise derived myokine irisin[J]. Front Aging Neurosci,2021,13:649929.
[8] COLAIANNI G, SANESI L, STORLINO G, et al. Irisin and bone: from preclinical studies to the evaluation of its circulating levels in different populations of human subjects[J]. Cells, 2019, 8(5): 451.
[9] SCHUMACHER M A, CHINNAM N, OHASHI T,et al.The structure of irisin reveals a novel intersubunit beta-sheet fibronectin type III (FNIII) dimer: implications for receptor activation[J]. J Biol Chem,2013,288(47):33738-33744.
[10] NIE Y,LIU D.N-Glycosylation is required for FDNC5 stabilization and irisin secretion[J]. Biochem,2017,474(18):3167-3177.
[11] ROCA-RIVADA A,CASTELA O C,SENIN LL,et al.FNDC5/irisin is not only a myokine but also an adipokine[J]. PLoS One,2013,8(9):60563.
[12] TIANO J P,SPRINGER D A, RANE S G.SMAD3 negatively regulates serum irisin and skeletal muscle FNDC5 and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha) during exercise[J]. J Biol Chem,2015,290(18):7671-7684.
[13] VARELA-RODRÍGUEZ B M,PENA-BELLO L,JUIZ-VALIÑA P, et al. FNDC5 expression and circulating irisin levels are modified by diet and hormonal conditions in hypothalamus, adipose tissue and muscle[J]. Sci Rep, 2016, 6: 29898.
[14] REZA M M,SUBRAMANIYAM N,SIM C M,et al.Irisin is a pro-myogenic factor that induces skeletal muscle hypertrophy and rescues denervation-induced atrophy[J]. Nature,2017,8(1):1104.
[15] ZHANG D,XIE T,LEUNG P S.Irisin ameliorates glucolipotoxicity-associated beta-cell dysfunction and apoptosis via AMPK signaling and anti-inflammatory actions[J]. Cell Physiol Biochem,2018,51(2):924-937.
[16] HUH J Y, DINCER F,MESFUM E,et al.Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans[J]. Int J Obes,2014,38(12):1538-1544.
[17] VAUGHAN R A, GANNON N P,BARBERENA M A,et al.Characterizationof the metabolic effects of irisin on skeletal muscle in vitro[J]. Diabetes Obes Metab,2014,16(8):711-718.
[18] CHOI Y K,KIM M K,BAE K H,et al. Serum irisin levels in new-onset type 2 diabetes[J]. Diabetes Res Clin Pract, 2013, 100(1): 96-101.
[19] KIM H J,SO B,CHOI M,et al. Resistance exercise training increases the expression of irisin concomitant with improvement of muscle function in aging mice and humans[J]. Exp Gerontol,2015,70:11-17.
[20] AMENGUAL J,GARCÍA-CARRIZO F J,ARREGUÍN A,et al.Retinoic acid increases fatty acid oxidation and irisin expression in skeletal muscle cells and impacts irisin in vivo[J]. Cell Physiol Biochem, 2018, 46(1): 187-202.
[21] KIM H, WRANN C D,JEDRYCHOWSKI M,et al.Irisin mediates effects on bone and fat via alphaV integrin receptors[J]. Cell,2018,175(7):1756-1768.
[22] 陈雪飞,方明,张靓.新的肌肉因子:Meteorin样因子[J]. 生理科学进展, 2019,50(4):289-292.
[23] ZHENG S L,LI Z Y,SONG J, et al. Metrnl: a secreted protein with new emerging functions[J].Acta Pharmacol Sin, 2016, 37(5): 571-579.
[24] LI Z Y,ZHENG S L,WANG P,et al.Subfatin is a novel adipokine and unlike Meteorin in adipose and brain expression[J]. CNS Neurosci Ther,2014,20(4): 344-354.
[25] NISHINO J,YAMASHITA K,HASHIGUCHI H,et al.Meteorin: a secreted protein that regulates glial cell differentiation and promotes axonal extension[J]. EMBO J,2004,23(9):1998-2008.
[26] USHACH I,BURKHARDT A M,MARTINEZ C, et al.METEORIN-LIKE is a cytokine associated with barrier tissues and alternatively activated macrophages[J]. Clin Immunol,2015,156(2):119-127.
[27] LI Z Y, SONG J, ZHENG S L,et al. Adipocyte metrnl antagonizes insulin resistance through PPARγ signaling[J]. Diabetes, 2015,64(12): 4011-4022.
[28] USHACH I,BURKHARDT A M,MARTINEZ C,et al.METEORIN-LIKE isacytokine associated with barrier tissues and alternatively activated macrophages[J]. Clin Immunol,2015,156(2): 119-127.
[29] BAHT G S, BAREJA A, LEE D E, et al.Meteorin-like facilitates skeletal muscle repair through a Stat3/IGF-1 mechanism[J]. Nat Metab, 2020,2(3):278-289.
[30] JORGENSEN J R,FRANSSON A,FJORD-LARSEN L,et al.Cometin is a novel neurotrophic factor that promotes neurite outgrowth and neuroblast migration in vitro and supports survival of spiral ganglion neurons in vivo[J]. Exp Neurol,2012,233(1):172-181.
[31] LEE J O, BYUN W S, KANG M J, et al. The myokine meteorin-like (metrnl) improves glucose tolerance in both skeletal muscle cells and mice by targeting AMPKα2[J]. FEBS J,2020,28(10)7:2087-2104.

FNDC5/Irisin、Metrnl与老年肌少症的研究进展

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 13

Metrics

推荐阅读 10

[1]	王楠楠, 林茜, 万顺伦. 老年重症肌无力伴胸腺瘤病人非手术治疗的远期疗效分析[J]. 实用老年医学, 2024, 38(10): 1064-1065.
[2]	唐泽丽, 李娟, 田芳, 唐欢, 颜欢, 李雨洁. 肌少症与口腔功能相关性的研究进展[J]. 实用老年医学, 2024, 38(10): 1074-1077.
[3]	陶营营, 王慧, 滕士超. 基于肠道菌群探讨从大肠角度治疗肌少症的中医内涵[J]. 实用老年医学, 2023, 37(10): 1056-1058.
[4]	韩斐, 姜从玉. 老年肌少症康复治疗技术新进展[J]. 实用老年医学, 2023, 37(1): 5-8.
[5]	薄莹莹, 莫永珍, 欧阳晓俊, 沈晓星, 朱海琼, 王洁, 刘小芹, 刘媚丽, 刘欢, 许家仁. 老年肌少症住院病人合并吞咽功能障碍的影响因素分析[J]. 实用老年医学, 2022, 36(6): 632-635.
[6]	李雯艳, 路娜, 阮海慧, 刘瑾, 袁蓉敬, 王叶同, 苏庆玲, 王艳红. 老年人肌少症性吞咽障碍患病率及危险因素的系统评价[J]. 实用老年医学, 2022, 36(4): 390-394.
[7]	高怡静, 吴秀萍. Apelin在肌少症中的研究进展[J]. 实用老年医学, 2021, 35(12): 1309-1312.
[8]	和丽丽, 李尧, 郭艺芳. 肠道菌群与肌少症的研究进展[J]. 实用老年医学, 2021, 35(10): 1080-1083.
[9]	詹莹莹, 陈锐, 刘琳妍, 葛健康. 肌少症与慢性心力衰竭的相关研究进展[J]. 实用老年医学, 2021, 35(7): 758-761.
[10]	朱倩倩, 刘扣英, 梅克文, 陈姝. 坐位运动对老年高跌倒风险肌少症病人肌肉功能及跌倒效能研究[J]. 实用老年医学, 2021, 35(7): 773-775.
[11]	陈颖, 赵梅. 光子治疗联合功能锻炼对老年终末期肾脏病病人的临床疗效[J]. 实用老年医学, 2021, 35(7): 776-779.
[12]	郭明贤, 郭峰, 高丽, 张桂红, 张秀芬, 吕淑萍. 西安城区群居老人痴呆的流行病学调查与分析[J]. 实用老年医学, 2010, 24(2): 125-127.
[13]	史岚平, 刘俊松, 王赎, 刘焕兵. 肌少症与心力衰竭和心肌细胞的相关性研究[J]. 实用老年医学, 2024, 38(7): 743-747.